Mike Kelly, CEO of NervGen, leads the charge in peptide therapeutics aimed at repairing the central nervous system. He shares his transformation from a sales background to a biotech leader, emphasizing the importance of mentorship in understanding complex biopharma science. The discussion highlights NervGen's innovative strategies for tackling neurodegenerative diseases and the challenges of peptide manufacturing. Kelly also reflects on navigating startup dynamics, funding strategies, and the significance of collaboration in biopharma success.
Mike Kelly's shift from sales to CEO at NervGen exemplifies the importance of integrating business acumen with scientific knowledge in life sciences.
NerveGen's focus on peptide therapeutics highlights their potential to bridge traditional small and large molecule therapies, particularly in treating neurological conditions.
The company's strategic emphasis on reliable manufacturing processes and regulatory navigation aims to ensure successful clinical trials and future commercial viability.
Deep dives
NerveGen's Mission and Peptide Development
NerveGen aims to enhance the nervous system's ability to repair itself following traumatic injury or disease, specifically through the use of therapeutic peptides. The company's lead peptide is currently undergoing clinical trials targeting spinal cord injury, with plans to expand into conditions such as stroke, Alzheimer's disease, multiple sclerosis, and amyotrophic lateral sclerosis. Peptides are regarded as a unique treatment modality due to their ability to be effective in ways that are not entirely understood, often bridging the gap between traditional small and large molecule therapies. Their increased vascular permeability and bioavailability present potential advantages when addressing neurological conditions.
Mike Kelly's Background and Career Journey
Mike Kelly has built a distinguished career in the life sciences sector, transitioning from a sales role in pharmaceuticals to becoming a seasoned biotech CEO. His journey began with a sales role where he gained valuable experience in understanding physician-patient interactions, ultimately leading to more significant roles in business development for various life sciences companies. By integrating his business acumen with knowledge of scientific principles, he learned to effectively communicate complex information to stakeholders. This foundation has positioned him to lead NerveGen as it navigates the complexities of peptide development and commercialization.
Challenges and Opportunities of Peptide Manufacturing
Peptide manufacturing poses unique challenges, primarily due to the complexities involved in consistent production and purification. NerveGen recognizes that securing reliable manufacturing processes is crucial for the successful development of their products. Kelly emphasizes the need for skilled personnel and reliable partnerships to overcome these hurdles, and he has engaged experts in the peptide field to ensure quality control. The strategic focus on manufacturing capabilities will ultimately play a significant role in the company’s ability to advance its therapeutic offerings.
Navigating Regulatory Landscapes
NerveGen operates in a unique regulatory environment where peptide therapies can sometimes be classified variably as biologics by the FDA. The company has been proactive in understanding these complexities and is preparing to engage with regulatory agencies as their clinical trials progress. By leveraging the knowledge of experienced team members, NerveGen aims to navigate the regulatory landscape effectively and ensure compliance while pushing its therapies through the development pipeline. This strategic foresight is essential in positioning the company for future growth and commercial success.
Future Prospects and Strategic Growth
NerveGen is focused on achieving significant milestones in clinical development, including completing enrollment for ongoing trials and generating data that will validate its therapeutic approaches. As the company progresses, there is optimism about the potential for uplisting to NASDAQ and attracting institutional investors, which would enhance its financial standing. The vision for August 2025 includes transitioning into a phase three study for their lead product and advancing new products into the pipeline concurrently. This growth trajectory reflects a commitment to leveraging clinical data to drive commercialization and tackle unmet medical needs in neurology.
Mike Kelly faced a self-reckoning before he took the job as CEO at NervGen, a company developing peptide therapeutics targeted specifically at central nervous system repair. The veteran of life sciences business development knew the ropes of the biotech C-suite. He’d been a CEO twice before. He knew how to launch drugs, having seen commercial success several times before. He even knew how to sell them—he’d started his career carrying the bag for TAP Pharmaceuticals. But all he knew about peptides was that they were challenging to manufacture consistently and purify. And he knew that manufacturing is where a lot of biopharma companies fall down. On this episode of the Business of Biotech, we learn how Kelly reconciled that truth, and how NervGen is now leading the way for peptide therapeutics in spinal cord injury and beyond.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
